The stock of Pacific Biosciences of California Inc (NASDAQ:PACB) last traded at $1.80, up 1.69% from the previous session.
PACB stock price is now -5.94% away from the 50-day moving average and -23.46% away from the 200-day moving average. The market capitalization of the company currently stands at $501.31M.
, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Kim Susan G., insider sold 19,782 shares of the company’s stock on Sep 30 ’24. The stock was sold for $34,065 at an average price of $1.72. Upon completion of the transaction, the insider now directly owns 695,654 shares in the company, valued at $1.25 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 30 ’24, Officer SUSAN KIM bought 19,782 shares of the business’s stock. A total of $34,061 was incurred on buying the stock at an average price of $1.72. A total of 4.26% of the company’s stock is owned by insiders.
During the past 12 months, Pacific Biosciences of California Inc has had a low of $1.16 and a high of $10.65. As of last week, the company has a debt-to-equity ratio of 2.03, a current ratio of 9.74, and a quick ratio of 8.64. The fifty day moving average price for PACB is $1.914 and a two-hundred day moving average price translates $2.352 for the stock.
The latest earnings results from Pacific Biosciences of California Inc (NASDAQ: PACB) was released for 2024-09-30. The net profit margin was -227.69% and return on equity was -64.80% for PACB. The company reported revenue of $39.97 million for the quarter, compared to $55.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -28.23 percent.
